Kiora In-Licenses Phase 3-Ready CRAO Drug KIO-401 for $3.5M Upfront, Up to $168.5M Milestones
KPRX sits 46% above its 52-week low of $1.765 on elevated volume (1.9× avg).
Summary
Kiora licensed ex-Asia rights to Senju's Phase 3-ready oral calpain inhibitor KIO-401 for CRAO, paying $3.5M upfront plus a $12.5M technology-transfer milestone and up to $168.5M in later milestones. The company now needs to raise capital to fund the Phase 3 trial it targets for 2027.
Key Events · M&A and Partnerships · KPRX
-
Exclusive KIO-401 License Signed
Kiora obtained exclusive development and commercialization rights to KIO-401 (mitucapistat), an oral calpain inhibitor, from Senju Pharmaceutical for all territories outside Asia, in the ophthalmology field.
-
Deal Economics: $3.5M Upfront
Kiora pays $3.5M upfront, a $12.5M technology-transfer milestone (a portion creditable against future milestones), up to $168.5M in regulatory and commercial milestones, and single-digit royalties on net sales outside Asia.
-
Phase 3 Trial Targeted for 2027
Senju completed Phase 2a and Phase 3 CRAO studies in Japan; Kiora plans a multinational Phase 3 registration trial of more than 100 patients starting in 2027, plus a Phase 2b NAION trial targeted for 2028.
-
Financing Needed to Fund Program
Kiora states it is evaluating financing alternatives to fund KIO-401 development, and discontinued KIO-104 R&D to prioritize KIO-401 and partnered KIO-301.
Analysis · KPRX · Life Sciences
Kiora just bought itself a Phase 3-ready asset. Senju has already run Phase 2a and Phase 3 CRAO trials in Japan, so Kiora skips years of early work and goes straight to a multinational registration trial targeted for 2027. The catch is cash: $3.5M is due now, a low-teen-million payment (the agreement states $12.5M) comes at technology transfer, and the company says it is evaluating financing alternatives — on a company this small, that almost certainly means selling stock. The $168.5M in milestones and single-digit royalties only pay out years from now, if the drug works. KIO-104 was discontinued to concentrate resources here.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KPRX was trading at $2.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $10.4M. The 52-week trading range was $1.76 to $2.91. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.